Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
- Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.
- 03/31/2025
|
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
- Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended December 31, 2024.
- 03/31/2025
|
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
- LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025.
- 03/28/2025
|
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance
- Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway pressure (CPAP) therapy, the current standard of care treatment.
- 02/24/2025
|
Best Momentum Stocks to Buy for January 8th
- VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
- 01/08/2025
|
New Strong Buy Stocks for January 8th
- SONY, VVOS, DXC, LIND and FNCO have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
- 01/08/2025
|
Vivos Therapeutics announces funding boost
- Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement.
- 12/23/2024
|
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at a purchase price of $4.935 per share in a registered direct offering priced at-the-market under Nasdaq rules.
- 12/23/2024
|
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy
- Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/18/2024
|
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call.
- 11/14/2024
|
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3
- Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses. Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.
- 11/14/2024
|
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
- LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024.
- 11/13/2024
|
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment
- Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.
- 10/08/2024
|
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
- New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children
- 10/08/2024
|
Vivos Therapeutics raises $4.3 from institutional investors
- Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering.
- 09/19/2024
|
Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment
- Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term.
- 09/18/2024
|
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
- Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model
- 09/18/2024
|
3 Trending Biotech Penny Stocks
- Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
- 08/22/2024
|
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Incorporated Operator Good day, everyone, and welcome to the Vivos Second Quarter 2024 Earnings Conference Call. [Operator Instructions] This conference is being recorded, and a replay of today's call will be available in Investor Relations section of Vivos' website and will be remaining posted there for the next 30 days.
- 08/15/2024
|
Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships
- Vivos Therapeutics (NASDAQ:VVOS) reported solid financial numbers for the second quarter of 2024 with a 19% increase in revenue. The company reported a revenue of $4.1 million compared to the $3.4 million reported in the same quarter of 2023, which the company said was primarily driven by increased sales of Vivos appliances and higher service revenue from Vivos Integrated Provider (VIP) enrollments.
- 08/14/2024
|
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
- Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2024.
- 08/14/2024
|
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
- LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024.
- 08/14/2024
|
Vivos Therapeutics reports positive results from pilot of provider-based model
- Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model. The medical technology firm on June 12, 2024, unveiled its new marketing and distribution model under which it seeks to drive revenue through partnerships with dentists and sleep treatment providers to offer patients with obstructive sleep apnea (OSA) a range of evidence-based treatment options, including Vivos' FDA-cleared CARE oral medical devices, oral appliances, and additive adjunctive therapies and methods.
- 06/27/2024
|
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
- 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances
- 06/27/2024
|
Vivos Therapeutics announces strategic alliance and $7.5M investment
- Vivos Therapeutics (NASDAQ:VVOS) announced a strategic marketing and distribution alliance with a multi-center sleep testing and treatment operator in Colorado. In a statement, Vivos said that the alliance marks a shift in Vivos' approach to distributing its advanced obstructive sleep apnea (OSA) treatments.
- 06/12/2024
|
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
- Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit
- 06/12/2024
|
Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics First Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.
- 05/17/2024
|
Vivos Therapeutics reports first quarter cost savings, launches revenue-generating initiative
- Vivos Therapeutics (NASDAQ:VVOS) told investors it continues to anticipate becoming cash flow positive from operations by the end of 2024 or the first quarter of 2025 as it successfully executes its cost-cutting initiatives and launches new strategic revenue initiative. The company, which is developing and commercializing proprietary treatments for sleep-related breathing disorders including obstructive sleep apnea (OSA), said that during the first quarter its operating expenses decreased by 22% or $1.6 billion from the year-ago quarter.
- 05/14/2024
|
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
- Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives
- 05/14/2024
|
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
- LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 financial results after market close today, Tuesday, May 14, 2024.
- 05/14/2024
|
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
- Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured Medicare reimbursement approval. The company announced earlier this week that its CARE oral medical devices, an alternative to continuous positive airway pressure (CPAP) for patients with OSA, have been approved for Medicare reimbursement by the Centers for Medicare and Medicaid Services (CMS).
- 04/11/2024
|
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
- Vivos Therapeutics (NASDAQ:VVOS) announced that its CARE oral medical devices for obstructive sleep apnea (OSA) have been approved for Medicare reimbursement. The company said this milestone achievement will allow millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
- 04/09/2024
|
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
- Vivos Therapeutics (NASDAQ: VVOS ) stock is on the rise Tuesday after the medical technology company announced an update for its CARE oral medical devices. The big news here that has VVOS stockholders excited is full reimbursement for these devices through Medicare.
- 04/09/2024
|
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
- First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults
- 04/09/2024
|
Vivos Therapeutics highlights path to cash flow positivity after FDA clearance
- Vivos Therapeutics (NASDAQ:VVOS) is on track to become cash flow positive by the end of 2024, its CEO revealed in its latest financial update. “Based on our progress to date and our revenue growth efforts for 2024, we continue to anticipate becoming cash flow positive from operations by the end of this year,” CEO Kirk Huntsman told shareholders.
- 04/01/2024
|
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
- Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea
- 03/28/2024
|
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
- LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its fourth quarter and full year 2023 financial results after market close today, Thursday, March 28, 2024.
- 03/28/2024
|
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant
- Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into a definitive agreement to immediately exercise an outstanding stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares for approximate proceeds of $4 million. The net proceeds will be used by the medical device company specializing in treatments for sleep-related breathing disorders for general corporate purposes.
- 02/15/2024
|
Vivos Therapeutics sees opportunities for its FDA-approved oral sleep apnea treatment amid CPAP market disruptions
- Vivos Therapeutics (NASDAQ:VVOS) is well-positioned to increase the adoption of its oral medical devices for the treatment of severe obstructive sleep apnea as patients seek alternatives to continuous positive airway pressure (CPAP). The company's Vivos CARE oral appliance in November 2023 received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea in adults along with positive airway pressure and/or myofunctional therapy, as required.
- 02/08/2024
|
Vivos Therapeutics sees revenue opportunities for its oral devices from recent market developments
- Vivos Therapeutics (NASDAQ:VVOS) sees significant new opportunities for its oral appliances targeting patients with sleep-related breathing disorders including obstructive sleep apnea (OSA) amid recent market developments. The company's Vivos CARE appliances in November 2023 were cleared by the US Food and Drug Administration (FDA) to treat moderate and severe OSA in adults along with positive airway pressure and/or myofunctional therapy as required, making them the only oral appliance to win FDA approval to treat severe OSA.
- 02/06/2024
|
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
- United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices
- 02/06/2024
|
Vivos Therapeutics reports surge in interest following FDA clearance for oral device treatment of sleep apnea
- Vivos Therapeutics (NASDAQ:VVOS) told investors it has experienced a surge in interest in the wake of the FDA 510(k) clearance from the US Food and Drug Administration (FDA) for its CARE (Complete Airway Repositioning and/or Expansion) oral medical devices targeting severe obstructive sleep apnea (OSA). The medical technology firm said the groundbreaking clearance, granted on November 28, 2023, marks the first time the FDA has approved an oral appliance for treating moderate and severe OSA in adults, aged 18 and older, complemented by positive airway pressure (PAP) and/or myofunctional therapy.
- 01/08/2024
|
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA
- New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA)), is pleased to announce that Vivos is seeing positive preliminary metrics following its November 28, 2023 announcement regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.
- 01/08/2024
|
Vivos Therapeutics announces women-led airway health event
- Vivos Therapeutics (NASDAQ:VVOS) announced that it will be hosting a women-led airway health-focused event at the Vivos Institute in Denver, Colorado, on February 1 and 2, 2024. The company said the event, “Empowering Women to Champion Airway,” will bring together prominent women in the medical and dental fields to drive collaboration around airway health.
- 12/11/2023
|
Black Swan: this small cap surged over 1000% last week
- Every so often, a move occurs in the stock market that can best be described as a 'black swan.' That is to say, a move that occurs in an individual stock that is exceedingly rare from a probabilistic standpoint.
- 12/04/2023
|
Vivos Therapeutics severe sleep apnea treatment's a ‘breakthrough', says CEO
- Vivos Therapeutics (NASDAQ:VVOS) Inc's recently announced FDA clearance for its oral appliances to treat severe obstructive sleep apnea (OSA) has sparked much investor interest, sending its stock price soaring more than 800% in a single trading session. Vivos CEO Kirk Huntsman spoke with Proactive following the announcement to explain the significance of this milestone and why it could be so transformative for the company.
- 12/01/2023
|
Vivos Therapeutics: Who is the medical device company creating frenzy in the markets?
- What a day it's been for Vivos Therapeutics (NASDAQ:VVOS). The medical technology company saw its shares shoot over 800% higher on Wednesday after news broke that it had received 510(k) clearance from the US Food and Drug Administration (FDA) for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances to treat severe obstructive sleep apnea (OSA) in adults.
- 11/29/2023
|
Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?
- Vivos Therapeutics (NASDAQ: VVOS ) stock is rocketing higher on Wednesday after the Food and Drug Administration (FDA) granted approval to its sleep apnea treatment device. According to a press release from the company, it has been granted 510(k) clearance from the FDA for its removable CARE oral applications.
- 11/29/2023
|
Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance
- Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.
- 11/29/2023
|
Vivos Therapeutics receives first ever FDA 510(k) clearance for oral device treatment of sleep apnea
- Vivos Therapeutics (NASDAQ:VVOS) announced that it has been granted 510(k) clearance from the US Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos' removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. The medical technology firm said with the unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for the company.
- 11/29/2023
|
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea
- Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).
- 11/29/2023
|
Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, participants are in a listen-only mode.
- 11/17/2023
|
Vivos Therapeutics showcases the impact of its cost-cutting initiatives with 3Q results
- Vivos Therapeutics (NASDAQ:VVOS) reported third-quarter results after the bell Tuesday, highlighting cost-cutting initiatives that CEO Kirk Huntsman says have positioned the company well moving forward. The medical technology company slashed operating expenses by 32% year-over-year and its net loss by 61%.
- 11/14/2023
|
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
- LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced it plans to release its third quarter 2023 financial results after market close on Tuesday, November 14, 2023.
- 11/09/2023
|
Vivos Therapeutics reveals 1-for-25 reverse stock split
- Vivos Therapeutics (NASDAQ:VVOS) has announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common shares effective at the start of trading on Friday, October 27, 2023. The medical technology company said among other considerations, the reverse split is intended to bring Vivos into compliance with the $1.00 minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market, and to make the prevailing prices of its shares more attractive to a broader group of institutional investors.
- 10/26/2023
|
Vivos Therapeutics inks distribution agreement for its oral devices with Lincare
- Vivos Therapeutics (NASDAQ:VVOS) announced it has signed a United States-wide distribution agreement for its oral appliances with Lincare, a leading supplier of in-home respiratory therapy products and services to about 1.8 million patients. The company noted that the distribution agreement comes on the heels of a distribution pilot with Lincare and will allow Vivos to engage with durable medical equipment (DME) companies in the United States.
- 10/24/2023
|
Vivos Therapeutics can help you get a better sleep (really)
- Better sleep is better health, period. But for many people, it's not that easy.
- 10/20/2023
|
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 10/12/2023
|
Vivos Therapeutics to kick off clinical trial at Stanford Medicine
- Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine. The medical technology company said study participants with moderate to severe obstructive sleep apnea (OSA) will be randomly assigned to either treatment with Vivos' DNA appliance or CPAP (continuous positive airway pressure), the current industry standard for OSA treatment.
- 10/11/2023
|
Vivos Therapeutics shares gains continue on Noum collaboration
- Vivos Therapeutics (NASDAQ:VVOS) shares continued to make gains on Thursday morning after the developer of oral appilances for the treatment of sleep-related disorders announced it has entered into an exclusive distribution agreement with Dubai-based Noum, a company that distributes products to healthcare providers and hospital networks treating patients with obstructive sleep apnea in the Middle East – North Africa (MENA) region. Shares of Vivos gained 15.5% in pre-market trade to US$0.35 after closing up almost 64% higher on Wednesday on the news it has entered into partnerships with Ormco and ON Demand Orthodontist.
- 10/05/2023
|
Vivos Therapeutics announces strategic agreements with Ormco and On Demand Orthodontist
- Vivos Therapeutics (NASDAQ:VVOS) has announced two strategic agreements that will expand its current product line of oral appliances for the treatment of breathing-related sleep disorders and are expected to create near-term revenue opportunities. Shares of Vivos jumped on the news, up 55% at US$0.29 in pre-market trade on Wednesday.
- 10/04/2023
|
Vivos Therapeutics previews upcoming conference featuring headline speaker James Nestor
- Vivos Therapeutics (NASDAQ:VVOS) said it will welcome best-selling author James Nestor to headline its Fifth Annual Breathing Wellness Conference. Nestor is the author of the best-selling book, Breath, in which he chronicles his own journey of discovery and healing.
- 10/02/2023
|
Vivos Therapeutics cost-cutting measures pay off in 2Q
- Vivos Therapeutics (NASDAQ:VVOS) said its cost-cutting initiatives drove a significant reduction in its net loss during the second quarter when compared to the same period in 2022. For the three months ended June 30, 2023, the company reduced its net loss by 21% to $1.5 million when compared to the year-ago quarter.
- 08/16/2023
|
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
- LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced that the Company intends to release its second quarter 2023 financial results after market close today, Wednesday, August 16, 2023.
- 08/16/2023
|
Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
- LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced it will reschedule its conference call to review its financial results for the second quarter ended June 30, 2023, previously scheduled for today at 5:00 p.m. (Eastern Time). Further details for the second quarter financial results conference call will be provided in a subsequent announcement.
- 08/14/2023
|
Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
- LITTLETON, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, today announced it plans to release its second quarter 2023 financial results after market close on Monday, August 14, 2023.
- 08/10/2023
|
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 06/13/2023
|
Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2023 Earnings Conference Call June 8, 2023 5:00 PM ET Company Participants Julie Gannon - IR Kirk Huntsman - Chairman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - ROTH Capital Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2023 Earnings Conference Call.
- 06/09/2023
|
Vivos Therapeutics reports rise in first quarter revenue
- Vivos Therapeutics Inc (NASDAQ:VVOS) has reported a rise in revenue to $3.9 million for its first quarter ended March 31, 2023, up from $3.6 million in the same period last year. The company said the increase in revenue was attributed to higher Vivos Integrated Provider (VIP) enrollments and increased revenue from seminars conducted at the Vivos Institute.
- 06/09/2023
|
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
- Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.26 per share a year ago.
- 06/08/2023
|
Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
- LITTLETON, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, today announced it plans to release its first quarter 2023 financial results after market close on Thursday, June 8, 2023.
- 06/06/2023
|
Vivos Therapeutics expects to reach positive cash flow a full quarter earlier thanks to new initiatives
- Vivos Therapeutics (NASDAQ:VVOS) Inc announced what it calls “a broad set of initiatives” designed to improve operational efficiencies, reduce expenses, and position the company to take advantage of growth opportunities. “Vivos has made major strides in recovering from challenges imposed by the COVID-19 pandemic on the dental industry which lost tens of thousands of qualified dental practice personnel, including many who were trained in the Vivos Method,” CEO Kirk Huntsman said in a statement.
- 05/09/2023
|
Vivos Therapeutics reports positive results from migraine study; shares skyrocket
- Vivos Therapeutics (NASDAQ:VVOS) said its recently acquired Preventive Oral Device, known as POD, has been shown to treat and prevent headaches in a clinical observational study, sending the company's shares skyrocketing. The US Food and Drug Administration (FDA) 510k-cleared device is worn during sleep to treat Temporomandibular Joint Dysfunction and its symptoms such as headaches and face or neck pain.
- 05/01/2023
|
Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2022 Results Conference Call March 30, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time participants are in a listen-only mode.
- 03/31/2023
|
Vivos Therapeutics says 2022 and early 2023 accomplishments sets stage for potential revenue growth this year
- Vivos Therapeutics (NASDAQ:VVOS), Inc has announced its fiscal 2022 financial results and provided an operational update, saying it believes its 2022 and early 2023 accomplishments, including the completion of a capital raise for net proceeds of about $7.4 million, cost reductions and a new technology acquisition, have set the stage for potential 2023 revenue growth. The medical device and technology company recorded revenue of $16 million for the full year ended December 31, 2022, which excludes about $2.5 million of Vivos Integrated Provider (VIP) enrollment revenue that is expected to be recognized during the next 17 months.
- 03/30/2023
|
VVOS Stock: 27.87% Decrease Exaplanation
- The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) fell by 27.87% in the most recent trading session. This is why.
- 03/01/2023
|
What Makes Penny Stocks Move? 3 Major Factors to Consider
- Here's why penny stocks climb in price The post What Makes Penny Stocks Move? 3 Major Factors to Consider appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/05/2023
|
The Sleep Apnea News That Has VVOS Stock Soaring Today
- Vivos Therapeutics (NASDAQ: VVOS ) stock is rocketing higher on Wednesday as investors react to positive news from the U.S. Food and Drug Administration (FDA). The FDA has approved Vivos Therapeutics' proprietary DNA appliance.
- 01/04/2023
|
7 Top Penny Stocks To Watch With Big News This Week
- Hot penny stocks to watch with news this week. The post 7 Top Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/04/2023
|
Vivos Therapeutics, Inc. (VVOS) Q2 and Q3 2022 Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 and Q3 2022 Earnings Conference Call December 20, 2022 5:00 PM ET Company Participants Julie Gannon - Chief of Staff and Investor Relations Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Alexander Nowak - Craig-Hallum Capital Group Operator Good day, everyone and welcome to the Vivos Therapeutics Second and Third Quarter 2022 Earnings Conference Call. At this time participants are in a listen-only mode.
- 12/20/2022
|
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call
- Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET
- 12/16/2022
|
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2022 Results - Earnings Call Transcript
- Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Company Representatives Kirk Huntsman - Chairman, Chief Executive Officer Brad Amman - Chief Financial Officer Julie Gannon - Investor Relations Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Scott Henry - ROTH Capital Steve Kruger - Foresight Investing Operator Good day, everyone and welcome to the Vivos Therapeutics Incorporated First Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode.
- 05/16/2022
|
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call
- Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET
- 03/31/2022
|
Vivos Therapeutics: First Take After The Broad Market Sell-Off
- Vivos Therapeutics, Inc. markets a jaw repositioning device that has the potential to cure patients' mild-to-moderate obstructive sleep apnea.
- 03/06/2022
|
Vivos Therapeutics to Participate in Upcoming Investor Conferences
- HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will participate in the following upcoming conferences.
- 03/02/2022
|
These 3 Penny Stocks Exploded Today, Here's Why
- Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/21/2022
|
Vivos Therapeutics Stock (VVOS): Why The Price Substantially Went Up Today
- The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 35% during intraday trading today. This is why it happened.
- 01/19/2022
|
Why Are Vivos Therapeutics Shares Surging Today?
- Vivos Therapeutics Inc (NASDAQ:VVOS) announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the quarter ended December 31, 2021, versus the three months ended December 31, 2020, Vivos reported an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists (known as Vivos Integrated Practices or VIPs).
- 01/19/2022
|
4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps
- Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/19/2022
|
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q3 2021 Results - Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
- HIGHLANDS RANCH, Colo., Oct. 19, 2021 /PRNewswire/ -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. ("Candid") , a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network.
- 10/19/2021
|
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
- HIGHLANDS RANCH, Colo., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. (“Candid”) , a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network.
- 10/18/2021
|
Children in Latest Clinical Study Show Significant Reduction of Tooth Decay After Treatment with Vivos Guides
- HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in pediatric patients after undergoing treatment using the Company's FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device.
- 10/13/2021
|
Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company's Technology for Obstructive Sleep Apnea
- Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apnea Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apnea
- 09/23/2021
|
Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
- Vivos management to present at 7:00 am EDT on September 13, 2021
- 09/08/2021
|
Implied Volatility Surging for Vivos (VVOS) Stock Options
- Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.
- 08/26/2021
|
Vivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment
- HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced a new cooperative relationship with Empower Sleep, a San Bernardino, Calif.-based company empowering patients with affordable, accessible and personalized telemedicine sleep care, to provide critical diagnostic and medical consultation services to people across North America who suffer from OSA.
- 08/26/2021
|
VVOS Stock: The Sleep Apnea Device News That Is Waking Up Vivos Therapeutics Shares
- Vivos Therapeutics (VVOS) stock is taking off on Monday morning after revealing clearance from the FDA for its sleep apnea device. The post VVOS Stock: The Sleep Apnea Device News That Is Waking Up Vivos Therapeutics Shares appeared first on InvestorPlace.
- 08/23/2021
|
Why Vivos Therapeutics Shares Are Soaring Today
- Vivos Therapeutics (NASDAQ: VVOS) is surging higher today after the company announced the U.S. Food and Drug Administration granted 510(k) market clearance to its mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults. The FDA clearance paves the way for expanded insurance reimbursement coverage for the mmRNA device.
- 08/23/2021
|
Vivos Therapeutics Shares Increase Over 45% Pre-Market: Why It Happened
- The shares of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 45% pre-market. This is why it happened.
- 08/23/2021
|
FDA Grants 510(k) Market Clearance to Vivos Therapeutics' mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea
- Part of the Vivos System Treatment, the mmRNA Device Represents a Highly Effective Non-Surgical, Non-Invasive and Non-Pharmaceutical Alternative for Patients Suffering from OSA
- 08/23/2021
|
Detailed Summary of Study Reporting that One in Four Patients Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment Now Available on Vivos Therapeutics Website
- HIGHLANDS RANCH, Colo., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced a more detailed summary of the national study results announced by the Company on July 13, 2021, is now available on the Company's website at: https://vivoslife.com/investor-relations/.
- 08/17/2021
|
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q2 2021 Results - Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Vivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update
- Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021
- 08/12/2021
|
Vivos Therapeutics: Reimagining Sleep
- Vivos Therapeutics' mission is to rid the world of obstructive sleep apnea (OSA).
- 07/30/2021
|
Vivos Therapeutics Opens State of the Art International Training Center In Denver
- The Vivos Institute Is Expected to Significantly Increase Vivos' Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities The Vivos Institute Is Expected to Significantly Increase Vivos' Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities
- 07/29/2021
|
Vivos Therapeutics Stock Price Increases Over 9%: Why It Happened
- The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 9% during intraday trading. This is why it happened.
- 07/07/2021
|
Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021
- Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?
- 07/07/2021
|
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2021 Results - Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2021 Results - Earnings Call Transcript
- 05/18/2021
|
Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.00 per share.
- 05/11/2021
|
Vivos Therapeutics Leads the Battle Against Obstructive Sleep Apnea (OSA)
- Sleeping well plays an essential role in physical health. In fact, it is part of the recovery, healing and repair process of many body functions.
- 04/15/2021
|
Vivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education
- HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical Director of Clinical Education, effective April 1, 2021.
- 04/14/2021
|
Investing in Sleep Apnea Companies
- Three stocks to have on your radar in the healthcare space.
- 04/09/2021
|
Vivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
- Full Year Revenue Increase of 15%
- 03/25/2021
|
Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit
- Vivos management to present at 1:30 pm Eastern Time on March 23, 2021
- 03/11/2021
|
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center
- Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea
- 03/08/2021
|
Vivos Therapeutics Submits FDA 510(k) Application for the Vivos mmRNA Oral Appliance
- If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage
- 02/02/2021
|
Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts
- Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success
- 01/29/2021
|
Why Cyclo, Vivos Therapeutics And More Are Moving Today
- Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins (CD) and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development.
- 01/05/2021
|
Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offering consisted of 3,500,000 shares of its common stock, as well as an additional 525,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.00 per share. Vivos' common stock is listed on the Nasdaq Capital Market under the ticker symbol “VVOS.”
- 12/15/2020
|
Vivos Therapeutics Announces Pricing of $21M Initial Public Offering
- HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020.
- 12/10/2020
|
